ReShape Lifesciences IncNASDAQ:RSLS
- LAST PRICE5.7500
- TODAY'S CHANGE (%)0.2000 (3.6036%)
- Bid / Lots5.0000/ 5
- Ask / Lots6.1100/ 3
- Open / Previous Close5.5500 / 5.5500
- Day Range
- 52 Week Range
- Volume25,522
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RSLS |
|---|---|---|
| 09:32 ET | 365 | 5.56 |
| 09:33 ET | 690 | 5.55 |
| 09:35 ET | 200 | 5.46 |
| 09:39 ET | 145 | 5.68 |
| 10:58 ET | 100 | 5.5956 |
| 11:00 ET | 100 | 5.6 |
| 11:30 ET | 391 | 5.521 |
| 11:32 ET | 1595 | 5.68 |
| 11:43 ET | 144 | 5.68 |
| 11:50 ET | 500 | 5.69 |
| 12:06 ET | 100 | 5.69 |
| 12:17 ET | 400 | 5.69 |
| 12:24 ET | 500 | 5.65 |
| 12:26 ET | 900 | 5.64 |
| 12:28 ET | 5880 | 5.62 |
| 12:32 ET | 600 | 5.7 |
| 12:33 ET | 400 | 5.7 |
| 12:35 ET | 100 | 5.75 |
| 12:42 ET | 235 | 5.735 |
| 12:44 ET | 200 | 5.75 |
| 12:50 ET | 100 | 5.75 |
| 02:03 ET | 200 | 5.7 |
| 02:05 ET | 372 | 5.7 |
| 02:12 ET | 566 | 5.79 |
| 02:39 ET | 895 | 5.8 |
| 02:41 ET | 800 | 5.8 |
| 02:45 ET | 200 | 5.75 |
| 03:26 ET | 409 | 5.75 |
| 03:30 ET | 113 | 5.7 |
| 03:37 ET | 300 | 5.74 |
| 03:39 ET | 100 | 5.715 |
| 03:46 ET | 180 | 5.79 |
| 04:00 ET | 1503 | 5.75 |
Nov 14, 2024
ReShape Lifesciences(R) Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
4:05PM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: ReShape Lifesciences(R) Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
ReShape Lifesciences(R) to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow JonesReShape Lifesciences(R) Receives Health Canada Approval for its Next-Generation Lap-Band(R) 2.0 FLEX, from 8:31AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:31AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
ReShape Lifesciences(R) Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Technology, from 8:31AM ET on Monday Nov 11, 2024 by Dow Jones
8:31AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ReShape Lifesciences Inc | 2.8M | -0.3x | --- |
Nuwellis Inc | 5.3M | 0.0x | --- |
Arypsa Inc | 30.0 | 0.0x | --- |
Avinger Inc | 2.7M | -0.1x | --- |
LogicMark Inc | 3.7M | 0.0x | --- |
Medite Cancer Diagnostics Inc | 90.0 | 0.0x | --- |
Company Information
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Contact Information
- Headquarters
- 1001 CALLE AMANECERSAN CLEMENTE, CA, United States 92673
- Phone
- 949-429-6680
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Dan Gladney
- President, Chief Executive Officer, Director
- Paul Hickey
- Chief Financial Officer
- Thomas Stankovich
- Independent Director
- Gary Blackford
- Independent Director
- Lori Mcdougal
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8M |
|---|---|
Revenue (TTM) | $8.2M |
Shares Outstanding | 506.7K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-18.59 |
Book Value | $16.48 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
